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Abstract
Introduction: We present a case of Streptococcus pneumoniae polyarticular septic arthritis in a patient with
rheumatoid arthritis receiving a single infusion of infliximab.
Case presentation: A 38-year-old Japanese man with a 5-year history of seronegative rheumatoid arthritis had
previously received sulphasalazine and methotrexate therapies and was on regular low-dose prednisolone therapy.
Despite these treatments, his disease activity remained high and infliximab was introduced in addition to
methotrexate, prednisolone, and folic acid. However, he was admitted to hospital with a fever of 40.6°C, chills, and
polyarthralgia eight days after the first infusion of infliximab. His joints were swollen, painful, and warm. Laboratory
data showed marked acute inflammation. He was diagnosed with bacterial septic polyarthritis, and emergency
surgical joint lavage and drainage was performed at the knees along with needle aspiration and lavage of the
ankles and right wrist. He was then given intravenous antibiotic therapy for 31 days. He made a good recovery
and was discharged on day 37.
Conclusions: We believe this is the first reported case of severe pneumococcal septic arthritis requiring
hospitalization in a patient treated with infliximab. S. pneumonia is now a well-recognized but uncommon cause of
polyarticular septic arthritis that can lead to cessation of therapy, as in our patient’s case.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory disease having a negative impact on the quality
of life [1]. Anti-tumor necrosis factor (TNF) therapy is
beneficial to RA patients because it suppresses inflam-
mation and joint destruction [2]. Thus, the percentage
of RA patients who are treated with anti-TNF agents is
steadily increasing. Infliximab (IFX), an anti-TNF mono-
clonal antibody, exhibits excellent effectiveness in RA;
however, many adverse events due to its use have been
reported in patients. TNF is an important cytokine
involved in initiating the protective immune response;
therefore, patients receiving this therapy are at a high
risk of infection. Staphylococcus aureus is the most com-
mon causative organism for septic polyarthritis with
multiple joints. Streptococcus pneumoniae is rare (5% of
septic arthritis cases) but is often responsible for polyar-
ticular infections than other organisms [3]. We report a
case of pneumococcal septic polyarthritis involving five
joints in a patient with seronegative RA following a sin-
gle infusion of IFX. This report suggests a possible asso-
ciation between the use of IFX and pneumococcal septic
polyarthritis, a severe and often fatal infection.
Case presentation
A 38-year-old Japanese man with seronegative RA, diag-
nosed in the year 2004 by using the American College of
Rheumatology (ACR) 1987 criteria, had received sulpha-
salazine and methotrexate (MTX) therapies before he vis-
ited our institute and was started on regular low-dose
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any medium, provided the original work is properly cited.prednisolone therapy. Despite these therapies, his RA dis-
ease activity remained high (tender and swollen joints at
the knees and ankles; patient global assessment score,
48/100 mm; C-reactive protein (CRP), 3.37 mg/dL; ery-
throcyte sedimentation rate (ESR), 48 mm/hour; matrix
metalloproteinase-3, 1531 ng/mL; Disease Activity Score
28-ESR, 4.57). The patient was obese (175 cm, 95 kg,
BMI (body mass index): 31.0); however, he neither had a
history of other medical problems (no viral infection and
a non-carrier) nor had he ever received surgical interven-
tion. He did not require intra-articular steroid injection.
IFX at a dose of 3 mg/kg (total dose, 285 mg) was intro-
d u c e di na d d i t i o nt oM T X( 1 0m gw e e k l y ) ,p r e d n i s o l o n e
(5 mg daily), and folic acid (5 mg weekly). He suffered no
immediate adverse effects and experienced excellent pain
relief in his knees and ankles the day after his first infu-
sion of IFX, but six days after infusion he presented with
a fever of 40°C, chills, and polyarthralgia including the
knees and ankles that persisted for two days, and he was
admitted to hospital.
At admission (day 0, eight days after his first infusion),
his body temperature was 40.6°C and he was tachycardic
(107 beats/minute) with 104/68 mmHg blood pressure.
H i sh e a r ts o u n d sw e r en o r m a la n dh eh a dn ov i s i b l e
rash. The affected joints (knees, ankles, and right wrist)
were swollen, painful, and warm. There was no evidence
of a primary source of infection. Laboratory data showed
marked acute inflammation (CRP, 31.0 mg/dL; white
blood cells, 19,200/mm
3) and pre-disseminated intravas-
cular coagulopathy and shock (prothrombin time (PT),
62.2%; activated partial thromboplastin time (APTT),
45.1%; fibrinogen, 804 mg/dL; serum fibrin/fibrinogen
degradation products (FDP), 14.7 μg/mL). Findings from
c h e s tc o m p u t e dt o m o g r a p h y( C T )( F i g u r e1 a ) ,u r i n e
smears, and cultures were all normal, and he had no
symptoms involving the abdomen or pelvis. Fluid drawn
from the knees was purulent and its smear revealed
numerous gram-positive cocci arranged in chains, which
were subsequently identified as S. pneumoniae at day
five. He was clinically diagnosed with bacterial septic
polyarthritis. Emergency surgical joint lavage and drai-
nage was then performed at the knees, along with nee-
dle aspiration and lavage of the ankles and right wrist
just after admission (day 0). He was treated with intra-
venous antibiotic therapy with cefazolin (2 g twice daily
at days 0 and one) and vancomycin (1 g once daily at
days one and two). At day two, a whole body CT
showed auxocardia and hydrothorax, but no pneumonia
or other abnormal findings (Figure 1b). Two blood cul-
tures taken at day 0 revealed penicillin-sensitive S. pneu-
moniae (minimal inhibitory concentration of penicillin
G ≤ 0.03 μg/mL) with no penicillin-resistant strains at
day two. He was switched to ceftriaxone (2 g twice daily
at day two and thereafter for a total of 29 days). He
a. b.
Figure 1 (a) Computed tomography of the chest. Hospital day 0. No abnormal findings. (b) Hospital day 2. Auxocardia and hydrothorax
extending to both lungs.
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rehabilitation. He was discharged on day 37 with 10 mg
weekly of MTX, when he returned to his preadmission
state (Figure 2).
Discussion
IFX is a human-murine, chimeric, anti-TNF monoclonal
antibody. It has been used in Japan since 2003 in the
treatment of RA in conjunction with MTX. It is known
to be very effective in decreasing inflammation, such as
t h a ti nR A .H o w e v e r ,i ti sa l s ok n o w nt h a ta n t i - T N F
therapy may be a risk factor for a number of infections;
in particular, IFX treatment is considered as a risk factor
for reactivation of latent tuberculosis [4-6]. A post-mar-
keting surveillance study in Japan showed that for RA
patients, IFX in combination with low-dose MTX was
well tolerated, but male gender, older age, Steinbrocker
stage III or IV and comorbid respiratory disease were
risk factors for bacterial pneumonia [7]. In addition, RA
disease severity in itself is known to be one of the strong
risk predictors of infection [8]. As mentioned above,
patients treated with anti-TNF agents are generally
believed to be at increased risk of bacterial infections
[9]. Conversely, another study found that the severity of
serious infections was not increased in anti-TNF-treated
patients compared with a DMARD (disease modifying
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Figure 2 Clinical course of the patient.C T ,c o m p u t e dt o m o g r a p h y ;C E Z ,c e f a z o l i n ;V C M ,v a n c o m y c i n ;C T R X ,c e f t r i a x o n e ;W B C ,w h i t eb l o o d
cells; CRP, C-reactive protein.
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the risks associated with the use of these agents, we
were very careful when deciding whether to administer
a particular biologic, and occasionally excluded immu-
nocompromised patients who had comorbidities, such
as diabetes mellitus, heart disease, viral hepatitis, and
lung disease, or those who were of an advanced age,
from these treatments. Although our patient was a 38-
year-old man with RA, but otherwise healthy, and did
not have any of the known risk factors for infection, he
developed pneumococcal septic polyarthritis.
Upper and lower respiratory tract infection, ear and
sinus infections, and meningitis are the most common
manifestations of S. pneumoniae infection [11]. Recently,
the emergence of S. pneumoniae strains with reduced
susceptibility to penicillin has been increasing. These
strains account for 2% t0 3% of cases [12-15]. Third-gen-
eration cephalosporins are the preferred first-line treat-
ment until reduced susceptibility to penicillin is ruled out
[11], but given the severity (possible sepsis or concur-
rence of meningitis) and the less frequent target (joints)
of our patient’si n f e c t i o n ,w ed i dn o tr u l eo u tt h ep r e -
sence of other strains with reduced susceptibility to peni-
cillin such as PISP or PRSP (penicillin-intermediate or
penicillin-resistant S. Pneumonia) .A sar e s u l tw ef i r s t
selected intravenous antibiotic therapy with the third-
generation cephalosporin ceftriaxone, rather than penicil-
lin G [11]. Therefore, from day two onwards, we used
ceftriaxone, which was effective as mentioned above. We
used vancomycin with ceftriaxone to control septic
arthritis until sensitivity to ceftriaxone was confirmed on
day two, but after that we stopped the use of vancomycin.
S. aureus is the most common causative organism in
septic arthritis in RA [16], and polyarticular septic
arthritis in RA patients has a 50% mortality rate [3].
The bones and joints are less frequently infected by S.
pneumoniae, which causes 3% to 10% of the septic
arthritis cases [12-14,17-19]. S. pneumoniae is more
often responsible for polyarticular infections than other
organisms [3]. Preceding or concurrent foci of extra-
articular infection are common in patients with pneu-
mococcal septic arthritis, probably because of other bac-
terial causes of joint infection. Bacteremia and
pneumonia are the most common extra-articular sites of
pneumococcal infection [13]. However, our patient had
no previous or coexisting infection such as pneumonia
(Figure 1a, b). Because a recent cohort study showed
that the adjusted hazard ratio for septic arthritis in
patients treated with anti-TNF agents was 2.3 (95% con-
fidence interval (CI) 1.2 to 4.4) and hazard estimates for
the first year of follow-up were found to be increased in
anti-TNF treatment [16], it is especially important to
carefully monitor early RA patients given anti-TNF
agents.
Conclusions
To the best of our knowledge, this is the first reported
case of pneumococcal septic polyarthritis following treat-
ment with IFX in a patient with RA. To avoid aggravation
of a patient’s illness and to prevent death due to severe
infection, it is important for clinicians to be aware of the
fact that use of TNF-inhibitors can lead to infections in
locations such as joints. Infections at these locations are
difficult to distinguish from the symptoms of a flare-up
of RA. Because delay in controlling an infection worsens
ap a t i e n t ’s RA disease activity during that period, it is
important to get any infection rapidly under control.
However, it is impossible to avoid accidental infections
such as in this case, irrespective of the level of precau-
tions. Recently, rheumatic treatment is being rapidly
adopted based on the concept of ‘treat-to-target’ and
therefore, we need to accumulate evidence from case stu-
dies to promote safe and effective treatments for RA and
to avoid diagnostic delays and therapeutic errors to
achieve maximum possible survival of patients.
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